Category: Featured News
February
1
2023
LifeLabs launches Signatera, offering Canadians an innovative and personalized approach to managing cancer
February 1, 2023. – Toronto, ON: LifeLabs is pleased to share the launch of SignateraTM, a highly sensitive, personalized molecular residual disease assay (MRD) test developed by Natera for treatmen...
Toronto, Dec. 21, 2022 – LifeLabs is excited to announce that we have been awarded the 2022 Workplace Benefits Award for our Coronavirus and benefits category from Benefits Canada, a leading publi...
December
15
2022
LifeLabs forms new collaboration with Natera to offer molecular residual disease (MRD) testing for cancer in Canada
LifeLabs is pleased to announce its new collaboration with Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, to offer* personalized testing for cancer in Canada through Natera’...
Toronto, ON – It hasn’t always been easy, but throughout the COVID-19 pandemic, our team has remained agile, customer-centric, caring, and collaborative. That’s why, last year, we re-examined ho...